Informações de Lipocine Inc

Mais detalhes de Lipocine Inc Empresa

Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. It is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.



Código da empresaLPCN

Nome da EmpresaLipocine Inc

Data de listagemMar 21, 2014

CEODr. Mahesh V. Patel, Ph.D.

Número de funcionários16

Tipo de títulosOrdinary Share

Fim do ano fiscalMar 21

Endereço675 S Arapeen Dr Ste 202

CidadeSALT LAKE CITY

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited States of America

Código postal84108-1295

Telefone18019947383

Sitehttps://www.lipocine.com/

Código da empresaLPCN

Data de listagemMar 21, 2014

CEODr. Mahesh V. Patel, Ph.D.

Executivos da empresa Lipocine Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Mahesh V. Patel, Ph.D.

President, Chief Executive Officer, Director

109.05K

+1.52%

Mr. John W. Higuchi

Director

40.80K

--

Dr. Nachiappan Chidambaram, Ph.D.

Senior Vice President - Research and Development

4.41K

+11.54%

Ms. Krista Fogarty

Principal Accounting Officer, Corporate Controller

1.07K

+44.84%

Dr. Richard Dana Ono, Ph.D.

Independent Director

831.00

--

Mr. Jeffrey A. (Jeff) Fink

Independent Director

386.00

--

Dr. Jill M. Jene, Ph.D.

Independent Director

--

Mr. Spyros Papapetropoulos, M.D., Ph.D.

Lead Independent Chairman of the Board

--

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Mahesh V. Patel, Ph.D.

President, Chief Executive Officer, Director

109.05K

+1.52%

Mr. John W. Higuchi

Director

40.80K

--

Dr. Nachiappan Chidambaram, Ph.D.

Senior Vice President - Research and Development

4.41K

+11.54%

Ms. Krista Fogarty

Principal Accounting Officer, Corporate Controller

1.07K

+44.84%

Dr. Richard Dana Ono, Ph.D.

Independent Director

831.00

--

Mr. Jeffrey A. (Jeff) Fink

Independent Director

386.00

--

Detalhamento da receita

Sem dados

Sem dados

Por Empresa

Por Região

Sem dados

Distribuição de ações

Atualizado em: dom, 17 de ago

Investidores

Tipos de investidores

Investidores

Proporção

The Vanguard Group, Inc.

4.15%

Patel (Mahesh V)

2.01%

BlackRock Institutional Trust Company, N.A.

1.65%

Geode Capital Management, L.L.C.

1.13%

Susquehanna International Group, LLP

0.85%

Outro

90.21%

Investidores

Proporção

The Vanguard Group, Inc.

4.15%

Patel (Mahesh V)

2.01%

BlackRock Institutional Trust Company, N.A.

1.65%

Geode Capital Management, L.L.C.

1.13%

Susquehanna International Group, LLP

0.85%

Outro

90.21%

Tipos de investidores

Investidores

Proporção

Investment Advisor

6.95%

Individual Investor

2.91%

Investment Advisor/Hedge Fund

2.15%

Hedge Fund

0.65%

Research Firm

0.05%

Outro

87.28%

Participação acionária institucional



Atualizado em: dom, 5 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

32

531.40K

9.81%

-38.58K

2025Q2

44

680.47K

12.56%

-41.55K

2025Q1

65

678.55K

12.68%

-110.89K

2024Q4

72

645.33K

12.07%

-219.30K

2024Q3

75

703.77K

13.16%

-136.61K

2024Q2

79

690.86K

12.92%

-132.01K

2024Q1

82

639.82K

12.02%

-214.82K

2023Q4

86

649.80K

12.29%

-222.39K

2023Q3

91

667.07K

12.61%

-176.35K

2023Q2

93

641.50K

12.32%

-239.33K

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

224.88K

4.15%

-1.40K

-0.62%

Jun 30, 2025

Patel (Mahesh V)

109.05K

2.01%

+1.63K

+1.52%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

89.27K

1.65%

--

Jun 30, 2025

Geode Capital Management, L.L.C.

61.08K

1.13%

+2.24K

+3.81%

Jun 30, 2025

Susquehanna International Group, LLP

46.02K

0.85%

+7.04K

+18.06%

Jun 30, 2025

Higuchi (John W)

40.80K

0.75%

--

Mar 31, 2025

Renaissance Technologies LLC

34.80K

0.64%

-2.71K

-7.23%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

23.86K

0.44%

-1.07K

-4.30%

Jun 30, 2025

State Street Investment Management (US)

18.63K

0.34%

--

Jun 30, 2025

Northern Trust Investments, Inc.

13.16K

0.24%

--

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: dom, 2 de nov

Nome

Proporção

iShares Core S&P Total U.S. Stock Market ETF

0%

DFA Dimensional US Sustainability Core 1 ETF

0%

Dimensional US Core Equity 1 ETF

0%

iShares Core S&P Total U.S. Stock Market ETF

Proporção0%

DFA Dimensional US Sustainability Core 1 ETF

Proporção0%

Dimensional US Core Equity 1 ETF

Proporção0%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

May 11, 2023

Merger

17→1

May 11, 2023

Merger

17→1

May 11, 2023

Merger

17→1

May 11, 2023

Merger

17→1

Data

Tipo

Proporção

May 11, 2023

Merger

17→1

May 11, 2023

Merger

17→1

May 11, 2023

Merger

17→1

May 11, 2023

Merger

17→1